CN115554388A - Nutrition balance formula for improving female polycystic ovarian hormone level and production process - Google Patents
Nutrition balance formula for improving female polycystic ovarian hormone level and production process Download PDFInfo
- Publication number
- CN115554388A CN115554388A CN202211412896.5A CN202211412896A CN115554388A CN 115554388 A CN115554388 A CN 115554388A CN 202211412896 A CN202211412896 A CN 202211412896A CN 115554388 A CN115554388 A CN 115554388A
- Authority
- CN
- China
- Prior art keywords
- pressing
- improving
- tablet
- polycystic ovarian
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940088597 hormone Drugs 0.000 title claims abstract description 31
- 239000005556 hormone Substances 0.000 title claims abstract description 31
- 230000002611 ovarian Effects 0.000 title claims abstract description 23
- 235000016709 nutrition Nutrition 0.000 title abstract description 15
- 230000035764 nutrition Effects 0.000 title abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 20
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 20
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 16
- 235000021324 borage oil Nutrition 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 12
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000010474 borage seed oil Substances 0.000 claims abstract description 11
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 11
- 229960000367 inositol Drugs 0.000 claims abstract description 11
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 10
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 10
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 8
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims abstract description 7
- 244000080208 Canella winterana Species 0.000 claims abstract description 7
- 235000008499 Canella winterana Nutrition 0.000 claims abstract description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 7
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims abstract description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229940017545 cinnamon bark Drugs 0.000 claims abstract description 7
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 7
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 7
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 7
- 229940027811 gymnema sylvestre leaf extract Drugs 0.000 claims abstract description 7
- 239000000600 sorbitol Substances 0.000 claims abstract description 7
- 238000003825 pressing Methods 0.000 claims description 60
- 238000009475 tablet pressing Methods 0.000 claims description 36
- 230000008093 supporting effect Effects 0.000 claims description 23
- 238000004806 packaging method and process Methods 0.000 claims description 21
- 239000004033 plastic Substances 0.000 claims description 18
- 230000000903 blocking effect Effects 0.000 claims description 13
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 claims description 9
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 6
- 235000001035 marshmallow Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 238000009434 installation Methods 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 229920006300 shrink film Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 3
- 244000208874 Althaea officinalis Species 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 235000010356 sorbitol Nutrition 0.000 abstract description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 4
- 239000011782 vitamin Substances 0.000 abstract description 4
- 235000013343 vitamin Nutrition 0.000 abstract description 4
- 229930003231 vitamin Natural products 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000036737 immune function Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000002175 menstrual effect Effects 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 206010036049 Polycystic ovaries Diseases 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract description 2
- 230000003821 menstrual periods Effects 0.000 abstract description 2
- 210000001672 ovary Anatomy 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000002485 urinary effect Effects 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000001732 althaea officinalis l. extract Substances 0.000 abstract 1
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 229960002920 sorbitol Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 241001307241 Althaea Species 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003098 androgen Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 150000008130 triterpenoid saponins Chemical class 0.000 description 3
- 240000000530 Alcea rosea Species 0.000 description 2
- 235000017334 Alcea rosea Nutrition 0.000 description 2
- 235000017303 Althaea rosea Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229930189936 Glyoxalase Natural products 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000009704 powder extrusion Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- -1 triterpenoid saponin compounds Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
- B30B11/02—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
- B30B11/04—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with a fixed mould
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B30—PRESSES
- B30B—PRESSES IN GENERAL
- B30B15/00—Details of, or accessories for, presses; Auxiliary measures in connection with pressing
- B30B15/32—Discharging presses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B37/00—Supplying or feeding fluent-solid, plastic, or liquid material, or loose masses of small articles, to be packaged
- B65B37/16—Separating measured quantities from supply
- B65B37/18—Separating measured quantities from supply by weighing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B43/00—Forming, feeding, opening or setting-up containers or receptacles in association with packaging
- B65B43/42—Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up state; Feeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging position; Locating containers or receptacles at the filling position; Supporting containers or receptacles during the filling operation
- B65B43/54—Means for supporting containers or receptacles during the filling operation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mechanical Engineering (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of ovary maintenance, in particular to a nutrition balance formula for improving the level of female polycystic ovary hormone and a production process, which comprises N-acetyl-L-cysteine, borage seed oil powder, cinnamon bark extract, inositol, coenzyme Q10, gymnema sylvestre leaf extract, marshmallow root extract, L-arginine hydrochloride, L-carnitine tartrate, D-chiral inositol, alpha-lipoic acid, banaba leaf extract, L-glutathione, sorbitol, microcrystalline cellulose and magnesium stearate; the nutritional formula has a good promoting effect on the improvement of the female polycystic ovarian hormone level, has a good guarantee on nutrition in the hormone level improving process, and has the effects of regulating female hormone, relieving discomfort in menstrual period, promoting urinary circulation, improving immunologic function, improving vitamin synthesis, reducing menstrual bleeding, reducing blood sugar, resisting oxidation and resisting aging.
Description
Technical Field
The invention belongs to the technical field of ovary maintenance, and particularly relates to a nutrition balance formula for improving the level of female polycystic ovarian hormone and a production process thereof.
Background
Polycystic ovarian onset is mostly seen in adolescence and is characterized by overhigh androgen, continuous no ovulation and change of ovarian polycystic. The endocrine is characterized in that the serum luteinizing hormone and the androgen are increased, and the ratio of estrone to estradiol is more than one. The treatment includes lowering androgen levels, regulating menstrual cycle, improving insulin resistance, and promoting ovulation. The treatment can be achieved by regulating diet and reducing weight to treat polycystic ovary. Also can regulate menstrual cycle by oral administration of short-acting contraceptive to restore menstrual cycle to normal state, thereby recovering ovulation and achieving the purpose of pregnancy. If there is no ovulation, the treatment may be with an ovulation-promoting drug.
In the prior art, when the female polycystic ovarian hormone level is regulated, the regulated formula is difficult to prepare and take, and the improvement of female nutrition balance is not noticed, so that the body state and the weight are obviously reduced in one period of improving the hormone level, and the health of people is influenced.
Therefore, it is necessary to develop a nutritional balance formula for improving the level of polycystic ovarian hormone in women and a production process thereof to solve the above problems.
Disclosure of Invention
In order to solve the problems in the background art, the invention provides a nutrition balance formula for improving the level of female polycystic ovarian hormone and a production process thereof.
In order to achieve the purpose, the invention provides the following technical scheme: a nutrition balance formula for improving the level of female polycystic ovarian hormone comprises the following components in parts by weight,
N-acetyl-L-cysteine: 85-90g;
borage seed oil powder: 48-55g;
cinnamon bark extract: 30-32g;
inositol: 28-30g;
coenzyme Q10:24-26g;
gymnema sylvestre leaf extract: 24-26g;
root extract of marshmallow: 24-26g;
l-arginine hydrochloride: 24-26g;
l-carnitine tartrate: 24-26g;
d-chiro-inositol: 14-15g;
alpha-lipoic acid: 12-15g;
banaba leaf extract: 2-3g;
l-glutathione: 1-1.5g;
sorbitol: 135-145g;
microcrystalline cellulose: 1.5-2g;
magnesium stearate: 0.3-0.4g.
Preferably, the specific content of each component is,
N-acetyl-L-cysteine: 87.5g;
borage seed oil powder: 50.00g;
cinnamon bark extract: 31.25g;
inositol: 29.19g;
coenzyme Q10:25.00g;
gymnema sylvestre leaf extract: 25.00g;
root extract of marshmallow: 25.00g;
l-arginine hydrochloride: 25.00g;
l-carnitine tartrate: 25.00g;
d-chiro-inositol: 14.56g;
alpha-lipoic acid: 14.00g;
banaba leaf extract: 2.50g;
l-glutathione: 1.25g;
sorbitol: 142.65g;
microcrystalline cellulose: 1.75g;
magnesium stearate: 0.35g.
Preferably, the particle size of the borage seed oil powder is less than 10 mu m, and the particle size of the magnesium stearate is less than 20 mu m.
The invention also provides a process for producing the nutritional balance formula for improving the level of female polycystic ovarian hormone, which comprises the following steps,
the method comprises the following steps: weighing the components in the formula according to the corresponding weight, pouring the weighed components into a mixer, crushing and primarily mixing the components by a crusher, and then pouring the mixture into the mixer;
step two: directly pouring the raw materials mixed in the mixer into a tablet press for tabletting and forming;
step three: and conveying the finished product after tabletting and forming to a packaging machine for bagging and sealing, boxing the finished product according to 30 bags/boxes, coding the packaging box, and sealing the packaging box by a shrink film.
Preferably, the tablet press in the second step comprises a workbench, a mounting table is arranged on one side of the workbench, a supporting plate is arranged on one side of the mounting table, a hopper is arranged at the top of the supporting plate, a plurality of powder leaking pipes are arranged at the bottom of the hopper, tablet pressing pipes are communicated with the bottoms of the powder leaking pipes, tablet pressing heads are arranged at one ends of the tablet pressing pipes, a tablet pressing cylinder is arranged on one side of each tablet pressing head, the tablet pressing cylinder is arranged on one side of the mounting table, and an automatic tablet stripping assembly is arranged on one side of the workbench.
Preferably, the automatic piece-releasing assembly comprises two identical pressing plates, a receiving groove is transversely formed in the surface of each pressing plate in a penetrating mode, the receiving groove is U-shaped, an inserting rod inserted into the working table is arranged at the bottom of each pressing plate, a return spring is fixedly connected between each inserting rod and the working table, a blocking rod is arranged at the top of each receiving groove, one end of each blocking rod transversely penetrates through the pressing plate at the position of the corresponding pressing pipe from the top of each pressing pipe, a chamfer is formed at the end of each blocking rod through beveling treatment, the height of the chamfer gradually increases towards the direction close to the mounting table, the top of the chamfer is flush with the side, opposite to the mounting table, of each pressing plate, the bottom end of each pressing plate is located on the side, opposite to the mounting table, and higher than the inner surface of the bottom of each receiving groove, the other end of each blocking rod is fixedly connected to the upper surface of the working table, one side of the working table extends out of a section with a thickness smaller than the thickness of the working table, a pressing cylinder is arranged at the top of each section, and a pressing cylinder is provided with a pressing plate, so that the two pressing plates are located between each pressing plate and the working table.
Preferably, a plurality of mounting rods are arranged on one surface of the pressing plate, which is back to the pressing plate, supporting grooves are formed in the end portions of the mounting rods, the upper surfaces of the supporting grooves are lower than the lower surfaces of the receiving grooves, the supporting grooves are used for placing plastic packaging bags, and vertical extension plates are arranged at the bottoms of the receiving grooves.
Preferably, the mount table leading flank has been seted up and has been placed the chamber, places intracavity portion and is provided with the sliding cabinet that has a plurality of spaces of placing, and the sliding cabinet top is provided with and has seted up a plurality of through-holes, and the mount table leading flank is provided with the bolt, and the bolt is installed at the mount table leading flank with vertical gliding mode.
The invention has the technical effects and advantages that:
1. the nutritional formula has a good promoting effect on the improvement of the female polycystic ovarian hormone level, has a good guarantee on nutrition in the hormone level improving process, and has the effects of regulating female hormone, relieving discomfort in menstrual period, promoting urinary circulation, improving immunologic function, improving vitamin synthesis, reducing menstrual bleeding, reducing blood sugar, resisting oxidation and resisting aging;
2. according to the automatic tablet releasing device, the tablet pressing cylinder is started, the tablet pressing cylinder pushes the tablet pressing head to move in the tablet pressing pipe until powder is extruded on the automatic tablet releasing component, then the automatic tablet releasing component works, the tablet pressing cylinder pushes a product pressed into tablets, the automatic tablet releasing component completes tablet releasing, automatic tablet releasing and collecting of finished products can be achieved, and tablet pressing efficiency is improved;
3. according to the invention, the tablets which are already positioned on the carrying groove are collected into the plastic packaging bag which is prevented from falling off at the position of the supporting groove, and when the carrying groove moves along with the pressing plate, the plastic packaging bag can be moved out from the bottom of the carrying groove, so that the supporting groove is closer to a worker, the worker can conveniently take out the plastic packaging bag from the supporting groove in a short distance and place a new plastic packaging bag, and when the supporting groove is positioned at the bottom of the carrying groove, the vertical extending plate plays a role in compressing the side face of the plastic packaging bag, so that the plastic packaging bag sleeved on the supporting groove can be prevented from falling off.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and those skilled in the art can also obtain other drawings according to the drawings without creative efforts.
FIG. 1 is a process flow diagram of the present invention for producing a nutritionally balanced formula for improving the levels of polycystic ovarian hormone in women;
fig. 2 is a schematic perspective view of a tablet press machine for use in the present invention;
FIG. 3 is a schematic view of one of the angles of FIG. 2 in the present invention;
fig. 4 is a front view of fig. 2 in the present invention.
In the figure: the automatic sheet discharging device comprises a workbench 1, an installation table 2, a supporting plate 3, a hopper 4, a powder leakage pipe 5, a sheet pressing pipe 6, a sheet pressing head 7, a sheet pressing cylinder 8, an automatic sheet discharging assembly 9, a sheet pressing plate 91, a receiving groove 92, an inserting rod 93, a return spring 94, a blocking rod 95, a pressing cylinder 96, a pressing plate 97, an installation rod 10, a supporting groove 11, a vertical extending plate 12, a sliding cabinet 13, a through hole 14 and a bolt 15.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments obtained by a person of ordinary skill in the art based on the embodiments of the present invention without any creative effort belong to the protection scope of the present invention;
in the description of the present invention, it is to be understood that the terms "length", "width", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like, indicate orientations or positional relationships based on the orientations or positional relationships illustrated in the drawings, and are used merely for convenience in describing the present invention and for simplicity in description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be constructed in a particular orientation, and be operated, and thus, are not to be construed as limiting the present invention. In addition, in the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
The invention provides a nutrition balance formula for improving the level of female polycystic ovarian hormone as shown in figure 1, which comprises the following components in parts by weight,
N-acetyl-L-cysteine: 85-90g; antioxidant and mucopolysaccharide agent and used as phlegm dissolving medicine.
Borage seed oil powder: 48-55g; borage oil, borage seed, and vegetable oil obtained by squeezing or low-temperature extracting. Is rich in natural gamma linolenic acid, and can improve female hormone health. Borage oil is useful in relieving menstrual and menopausal complaints and in helping women regulate hormone health by natural means.
Cinnamon bark extract: 30-32g; has obvious enhancement effect on the immunologic function of the human body; the action mechanism is that the medicine can enhance the proliferation and differentiation of human T lymphocytes and B lymphocytes and enhance the functions of the human T lymphocytes and B lymphocytes; enhancing the killing function of the killer cells and the phagocytic function of mononuclear phagocytes.
Inositol: 28-30g; inositol is a "biological active" which participates in the metabolism of the body and has various functions of immunity, prevention and treatment of some diseases, and is also a growth factor of some microorganisms in the intestine, and in the case of deficiency of other vitamins, it can stimulate the microorganisms lacking the vitamins to synthesize the vitamins.
Coenzyme Q10:24-26g; is one of the participating substances of electron transfer chain and aerobic respiration in the mitochondria of eukaryotic cells.
Gymnema sylvestre leaf extract: 24-26g; the extract mainly comprises total triterpenoid saponin, flavonoid glycoside, anthocyanidin, polysaccharide, etc., wherein the content of total triterpenoid saponin is 50-99%, and the total triterpenoid saponin contains six new triterpenoid saponin compounds 25-40%. The extract has effects of lowering blood sugar, reducing blood lipid and resisting blood platelet aggregation.
Root extract of marshmallow: 24-26g; hollyhock root, chinese medicine name. Is root of Althaea rosea Rosea (Linn.) Cavan of Malvaceae. Distributed in Shaanxi, gansu, henan, hubei, sichuan, guizhou, etc. Has the effects of clearing heat, promoting diuresis, cooling blood, stopping bleeding, removing toxic substance and expelling pus. Can be used for treating stranguria, leukorrhagia, dysentery, hematemesis, metrorrhagia, traumatic hemorrhage, pyocutaneous disease, toxic swelling, scald, and burn.
L-arginine hydrochloride: 24-26g; the effective component of L-arginine hydrochloride is L-arginine, and can be used in medicine for promoting wound healing, stimulating immune system development, promoting hormone secretion, promoting urine circulation, reducing ammonia content in blood, and treating blood ammonia poisoning.
L-carnitine tartrate: 24-26g; has a pleasant acidic odor. Is easily soluble in water and is not easily soluble in organic solvents. The L-carnitine is an amino acid analog for promoting fat to be converted into energy, has no toxic or side effect on human bodies, is particularly suitable for being matched with people to do aerobic exercise to reduce fat, and has obvious effect. Can be used in medicine and health product, food additive, etc.
D-chiro-inositol: 14-15g; d-chiro-inositol (DCI) is one of nine isomers of inositol that is optically active. In recent years, researches show that the DCI has the functions of promoting liver lipid metabolism by inositol, and also has the physiological functions of sensitizing insulin, reducing blood sugar, improving ovulation condition of patients with polycystic ovary syndrome (PCOS), regulating hormone balance, improving menstrual disorder, resisting oxidation, aging and inflammation, and the like.
Alpha-lipoic acid: 12-15g; alpha-lipoic acid is the only universal oxygen activator with fat solubility and water solubility, and the acting force of the lipoic acid is longer than that of other antioxidants. The lipoic acid can balance blood sugar, promote the absorption of glucose, improve the blood sugar control of the diabetic patients and reduce the use of insulin or hypoglycemic drugs for the patients.
Banaba leaf extract: 2-3g; banaba leaf is a plant traditionally used in india and philippines for the treatment of hyperglycemia and diabetes.
L-glutathione: 1-1.5g; widely distributed in animal and plant cells, and has high content in liver and crystal. It is the prosthetic group of glyceraldehyde phosphate dehydrogenase and the coenzyme of glyoxalase and triose phosphate dehydrogenase, and participates in tricarboxylic acid cycle and sugar metabolism in vivo, so that a human body obtains high energy. It can activate in vivo Sulfhydryl (SH) enzyme, such as cholinesterase, and is associated with allergic diseases, and can protect organism from poisoning by heavy metal and epoxy compound. Can promote metabolism of carbohydrate, fat and protein, control cell metabolic process, and has radioprotective and melanin pigmentation inhibiting effects.
Sorbitol: 135-145g; has cool sweet taste, sweetness about half of that of cane sugar, calorific value similar to that of cane sugar, and no dental caries when used as a sweetening agent.
Microcrystalline cellulose: 1.5-2g; because of the special properties of low polymerization degree, large specific surface area and the like, the microcrystalline cellulose is widely applied to the industries of medicine, food, cosmetics and the like.
Magnesium stearate: 0.3-0.4g. Mainly used as lubricant, anti-sticking agent and glidant. Is especially suitable for granulating oil and extract medicines, and the prepared granules have good fluidity and compressibility. As a glidant in direct compression.
The concrete contents of the components are as follows,
N-acetyl-L-cysteine: 87.5g;
borage seed oil powder: 50.00g;
cinnamon bark extract: 31.25g;
inositol: 29.19g;
coenzyme Q10:25.00g;
gymnema sylvestre leaf extract: 25.00g;
root extract of marshmallow: 25.00g;
l-arginine hydrochloride: 25.00g;
l-carnitine tartrate: 25.00g;
d-chiro-inositol: 14.56g;
alpha-lipoic acid: 14.00g;
banaba leaf extract: 2.50g;
l-glutathione: 1.25g;
sorbitol: 142.65g;
microcrystalline cellulose: 1.75g;
magnesium stearate: 0.35g.
The particle size of the borage seed oil powder is less than 10 mu m, and the particle size of the magnesium stearate is less than 20 mu m.
The invention also provides a process for producing the nutritional balance formula for improving the level of female polycystic ovarian hormone, which comprises the following steps,
the method comprises the following steps: weighing the components in the formula according to the corresponding weight, pouring the weighed components into a mixer, crushing and primarily mixing the components by a crusher, and then pouring the mixture into the mixer;
step two: directly pouring the raw materials mixed in the mixer into a tablet press for tabletting and forming;
step three: and conveying the finished product after tabletting and forming to a packaging machine for bagging and sealing, boxing the finished product according to 30 bags/boxes, coding the packaging box, and sealing the packaging box by a shrink film.
Referring to the attached drawings 2-4 of the specification, the tablet press in the step two comprises a workbench 1, a mounting table 2 is arranged on one side of the workbench 1, a supporting plate 3 is arranged on one side of the mounting table 2, a hopper 4 is arranged on the top of the supporting plate 3, a plurality of powder leaking pipes 5 are arranged at the bottom of the hopper 4, the bottom of each powder leaking pipe 5 is communicated with a tablet pressing pipe 6, a tablet pressing head 7 is arranged at one end of each tablet pressing pipe 6, a tablet pressing cylinder 8 is arranged on one side of each tablet pressing head 7, the tablet pressing cylinder 8 is arranged on one side of the mounting table 2, and an automatic tablet stripping assembly 9 is arranged on one side of the workbench 1.
When carrying out the preforming, put into hopper 4 with the powder after mixing, leak the inside sensor that can monitor the powder that sets up of powder pipe 5, the content of the whereabouts of powder in leaking powder pipe 5 carries out quantitative control, the powder of whereabouts enters into in preforming pipe 6, start preforming cylinder 8 afterwards, preforming cylinder 8 pushes away the motion of tablet head 7 in preforming pipe 6, until with the powder extrusion on automatic piece subassembly 9 that takes off, automatic piece subassembly 9 work that takes off afterwards, the product that preforming cylinder 8 will suppress the piece promotes, automatic piece subassembly 9 that takes off accomplishes the piece, can realize that the finished product is automatic to take off the piece and collect, the efficiency of preforming is improved.
Referring to the attached drawings 2-4 of the specification, the automatic release assembly 9 includes two identical pressing plate plates 91, a receiving groove 92 is transversely penetrated through the surface of the pressing plate 91, the receiving groove 92 is U-shaped, an insertion rod 93 inserted into the workbench 1 is arranged at the bottom of the pressing plate 91, a return spring 94 is fixedly connected between the insertion rod 93 and the workbench 1, a blocking rod 95 is arranged at the top of the receiving groove 92, one end of the blocking rod 95 transversely penetrates through the pressing plate 91 at the position of the pressing pipe 6 from the top of the pressing pipe 6, and is obliquely cut to form an oblique cut, the height of the oblique cut is gradually increased toward the direction close to the workbench 2, the top of the oblique cut is flush with one surface of the pressing plate 91 facing the workbench 2, the bottom end of the oblique cut is located on the side of the pressing plate 91 opposite to the workbench 2 and higher than the inner surface of the bottom of the receiving groove 92, the other end of the blocking rod 95 is fixedly connected to the upper surface of the workbench 1, a section of the workbench 1 with a thickness smaller than that of the oblique cut, a pressing plate 96 is arranged at the top of the section, and a pressing cylinder 96 is arranged at the end of the pressing plate 97, so that the pressing plate 91 is located between the pressing plate 97.
The automatic stripping assembly 9 works as follows: the powder is pressed on the tablet pressing plate 91 at the tablet pressing head 7, the powder is pressed and molded, then the pressing cylinder 96 drives the pressing plate 97 to move, at the moment, the return spring 94 is in a compression state, the return spring 94 can recover, the pressing plate 91 is driven by the return spring 94 to separate from the tablet pressing tube 6, then the tablet pressing cylinder 8 drives the tablet pressing head 7, the tablet pressing head 7 pushes the tablets out of the tablet pressing tube 6 and falls onto the inclined plane of the blocking rod 95, the tablets slide into the receiving groove 92 along the inclined plane, then the pressing cylinder 96 and the pressing plate 97 are controlled to work again, the tablet pressing plate 91 is pushed again and attached to the tablet pressing tube 6, in the moving process of the tablet pressing plate 91, the tablet pressing plate 91 drives the receiving groove 92 to move, the tablets in the receiving groove 92 are blocked by the end part of the blocking rod 95 and gradually move on the surface of the receiving groove 92, and finally fall from the receiving groove 92, automatic tablet releasing and collection of the tablets are realized, and the tablet pressing efficiency is improved.
Referring to the attached drawings 2-4 of the specification, a plurality of mounting rods 10 are arranged on one surface of the pressing plate 97, which is opposite to the pressing plate 91, supporting grooves 11 are arranged at the end parts of the mounting rods 10, the height of the upper surfaces of the supporting grooves 11 is lower than that of the lower surfaces of the receiving grooves 92, the supporting grooves 11 are used for placing plastic packaging bags, and vertical extending plates 12 are arranged at the bottoms of the receiving grooves 92.
In carrying out new preforming in-process, can collect the plastic envelope bag that support groove 11 department prevented with the tablet that has been located on accepting groove 92, and when accepting groove 92 removed along with pressure strip 97, the plastic envelope bag can shift out from accepting groove 92 bottom, make support groove 11 more be close to the staff, make things convenient for when personnel closely take out the plastic envelope bag from support groove 11 and place new plastic envelope bag, support groove 11 is when being located accepting groove 92 bottom, erect and prolong board 12 and play the effect that the side compressed tightly to the plastic envelope bag, can prevent that the plastic envelope bag of cover on supporting groove 11 from droing.
Referring to the attached drawing 1 of the specification, a placing cavity is formed in the front side face of the mounting table 2, a sliding cabinet 13 with a plurality of placing spaces is arranged in the placing cavity, a plurality of through holes 14 are formed in the top of the sliding cabinet 13, a bolt 15 is arranged on the front side face of the mounting table 2, and the bolt 15 is mounted on the front side face of the mounting table 2 in a vertically sliding mode.
The plastic packaging bag is placed inside the sliding cabinet 13, when one of the plastic packaging bags in the placing space is used up, the sliding cabinet 13 is pulled to move towards the outside of the placing cavity, so that the next placing space is exposed, the inserting pin 15 is inserted into the through hole 14, the vibration generated during the working of the equipment is prevented, the sliding condition of the sliding cabinet 13 is caused, the plastic packaging bag in the placing cavity is prevented from being exposed, and the cleanness is guaranteed.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (8)
1. A nutritionally balanced formula for improving the level of female polycystic ovarian hormone, comprising: the formula comprises the following components in parts by weight,
N-acetyl-L-cysteine: 85-90g;
borage seed oil powder: 48-55g;
cinnamon bark extract: 30-32g;
inositol: 28-30g;
coenzyme Q10:24-26g;
gymnema sylvestre leaf extract: 24-26g;
root extract of marshmallow: 24-26g;
l-arginine hydrochloride: 24-26g;
l-carnitine tartrate: 24-26g;
d-chiro-inositol: 14-15g;
alpha-lipoic acid: 12-15g;
banaba leaf extract: 2-3g;
l-glutathione: 1-1.5g;
sorbitol: 135-145g;
microcrystalline cellulose: 1.5-2g;
magnesium stearate: 0.3-0.4g.
2. The nutritionally balanced formulation for improving women's polycystic ovarian hormone levels as in claim 1, wherein: the concrete contents of the components are as follows,
N-acetyl-L-cysteine: 87.5g;
borage seed oil powder: 50.00g;
cinnamon bark extract: 31.25g;
inositol: 29.19g;
coenzyme Q10:25.00g;
gymnema sylvestre leaf extract: 25.00g;
root extract of marshmallow: 25.00g;
l-arginine hydrochloride: 25.00g;
l-carnitine tartrate: 25.00g;
d-chiro-inositol: 14.56g;
alpha-lipoic acid: 14.00g;
banaba leaf extract: 2.50g;
l-glutathione: 1.25g;
sorbitol: 142.65g;
microcrystalline cellulose: 1.75g;
magnesium stearate: 0.35g.
3. The nutritionally balanced formulation for improving the levels of polycystic ovarian hormones in women according to claim 1, wherein: the particle size of the borage seed oil powder is less than 10 mu m, and the particle size of the magnesium stearate is less than 20 mu m.
4. A process for producing a nutritionally balanced formulation for improving the levels of polycystic ovarian hormone in women according to claims 1-3, wherein: the process comprises the following steps of,
the method comprises the following steps: weighing the components in the formula according to the corresponding weight, pouring the weighed components into a mixer, crushing and primarily mixing the components by a crusher, and then pouring the mixture into the mixer;
step two: directly pouring the raw materials mixed in the mixer into a tablet press for tabletting and forming;
step three: and conveying the finished product after tabletting and forming to a packaging machine for bagging and sealing, boxing the finished product according to 30 bags/boxes, coding the packaging box, and sealing the packaging box by a shrink film.
5. The process for producing a nutritionally balanced formula for improving the levels of female polycystic ovarian hormone of claim 4, wherein: the tablet press in the second step comprises a workbench (1), wherein a mounting table (2) is arranged on one side of the workbench (1), a supporting plate (3) is arranged on one side of the mounting table (2), a hopper (4) is arranged at the top of the supporting plate (3), a plurality of powder leaking pipes (5) are arranged at the bottom of the hopper (4), a tablet pressing pipe (6) is communicated with the bottom of each powder leaking pipe (5), a tablet pressing head (7) is arranged at one end of each tablet pressing pipe (6), a tablet pressing cylinder (8) is arranged on one side of each tablet pressing head (7), the tablet pressing cylinder (8) is arranged on one side of the mounting table (2), and an automatic tablet releasing assembly (9) is arranged on one side of the workbench (1).
6. The process for producing a nutritionally balanced formula for improving the levels of female polycystic ovarian hormone of claim 5, wherein: the automatic release sheet assembly (9) comprises two identical pressing sheet plates (91), a bearing groove (92) transversely penetrates through the surfaces of the pressing sheet plates (91), the bearing groove (92) is of a U shape, an insertion rod (93) inserted into the inner part of the workbench (1) is arranged at the bottom of each pressing sheet plate (91), a return spring (94) is fixedly connected between the insertion rod (93) and the workbench (1), a blocking rod (95) is arranged at the top of the bearing groove (92), one end of the blocking rod (95) transversely penetrates through the pressing sheet plate (91) at the position of the pressing sheet pipe (6) by the top of the pressing sheet pipe (6), the end forms a chamfer surface through chamfering processing, the height of the chamfer surface is gradually increased towards the direction close to the installation table (2), the top of the chamfer surface is flush with the pressing sheet plate (91) against the installation table (2), the bottom of the pressing sheet plate (91) is arranged on one side opposite to the installation table (2) and is higher than the inner surface at the bottom of the bearing groove (92), the other end of the blocking rod (95) is fixedly connected to the upper surface of the workbench (1), a pressing sheet plate (1), and a pressing sheet plate (96) with a pressing cylinder (97) with a pressing cylinder, and a pressing cylinder end portion (97) is arranged between the pressing sheet plate (96) and a pressing cylinder end portion is arranged between the pressing sheet cylinder (97).
7. The process for producing a nutritionally balanced formula for improving the levels of female polycystic ovarian hormone of claim 6, wherein: the pressing plate (97) is provided with a plurality of mounting rods (10) on one surface back to the pressing plate (91), supporting grooves (11) are formed in the end portions of the mounting rods (10), the height of the upper surface of each supporting groove (11) is lower than that of the lower surface of each receiving groove (92), the supporting grooves (11) are used for placing plastic packaging bags, and vertical extending plates (12) are arranged at the bottoms of the receiving grooves (92).
8. The process for producing a nutritionally balanced formula for improving the levels of female polycystic ovarian hormone of claim 5, wherein: the mounting table is characterized in that a placing cavity is formed in the front side face of the mounting table (2), a plurality of sliding cabinets (13) with placing spaces are arranged in the placing cavity, a plurality of through holes (14) are formed in the tops of the sliding cabinets (13), a bolt (15) is arranged on the front side face of the mounting table (2), and the bolt (15) is mounted on the front side face of the mounting table (2) in a vertical sliding mode.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022113655330 | 2022-11-03 | ||
| CN202211365533 | 2022-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115554388A true CN115554388A (en) | 2023-01-03 |
Family
ID=84770140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211412896.5A Pending CN115554388A (en) | 2022-11-03 | 2022-11-11 | Nutrition balance formula for improving female polycystic ovarian hormone level and production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115554388A (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
| CN105310074A (en) * | 2014-07-30 | 2016-02-10 | 密涅瓦研究实验室有限公司 | Anti-aging antioxidant nutritional supplement for the improvement of the integumentary system |
| CN105639385A (en) * | 2016-02-02 | 2016-06-08 | 南京通孚轻纺有限公司 | Liquid making infants comfortable and preparation method thereof |
| CN105641674A (en) * | 2016-01-26 | 2016-06-08 | 李华红 | Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof |
| CN105725212A (en) * | 2016-03-07 | 2016-07-06 | 马占平 | Camellia nitidissima lozenge and preparation method thereof |
| CN105792818A (en) * | 2013-12-05 | 2016-07-20 | 希格马托制药工业公司 | Composition useful for promoting female fertility |
| CN107469064A (en) * | 2016-06-08 | 2017-12-15 | 广州艾玫格生物科技有限公司 | Biological antiallergic compound |
| CN108524814A (en) * | 2018-05-14 | 2018-09-14 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose |
| CN109745359A (en) * | 2019-03-08 | 2019-05-14 | 储殷 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
| CN112316122A (en) * | 2020-11-02 | 2021-02-05 | 山东省大健康精准医疗产业技术研究院 | Composition for treating polycystic ovarian syndrome and preparation method and application thereof |
| CN113332329A (en) * | 2021-06-16 | 2021-09-03 | 安徽安力肽生物科技有限公司 | Pueraria flavone tablet and preparation method thereof |
| CN113398084A (en) * | 2021-07-02 | 2021-09-17 | 安徽省先锋制药有限公司 | Levetiracetam sustained release tablet and preparation method thereof |
| CN216488192U (en) * | 2021-12-13 | 2022-05-10 | 山东中信迪生电源有限公司 | Tabletting device for battery pressure surface gasket |
-
2022
- 2022-11-11 CN CN202211412896.5A patent/CN115554388A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103431392A (en) * | 2013-08-29 | 2013-12-11 | 青岛海百合生物技术有限公司 | Composite marine food for special dietary uses for diabetics |
| CN105792818A (en) * | 2013-12-05 | 2016-07-20 | 希格马托制药工业公司 | Composition useful for promoting female fertility |
| CN105310074A (en) * | 2014-07-30 | 2016-02-10 | 密涅瓦研究实验室有限公司 | Anti-aging antioxidant nutritional supplement for the improvement of the integumentary system |
| CN105641674A (en) * | 2016-01-26 | 2016-06-08 | 李华红 | Compound nanometer preparation for treating diabetes mellitus type 2 and preparation method thereof |
| CN105639385A (en) * | 2016-02-02 | 2016-06-08 | 南京通孚轻纺有限公司 | Liquid making infants comfortable and preparation method thereof |
| CN105725212A (en) * | 2016-03-07 | 2016-07-06 | 马占平 | Camellia nitidissima lozenge and preparation method thereof |
| CN107469064A (en) * | 2016-06-08 | 2017-12-15 | 广州艾玫格生物科技有限公司 | Biological antiallergic compound |
| CN108524814A (en) * | 2018-05-14 | 2018-09-14 | 刘德平 | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose |
| CN109745359A (en) * | 2019-03-08 | 2019-05-14 | 储殷 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
| CN112316122A (en) * | 2020-11-02 | 2021-02-05 | 山东省大健康精准医疗产业技术研究院 | Composition for treating polycystic ovarian syndrome and preparation method and application thereof |
| CN113332329A (en) * | 2021-06-16 | 2021-09-03 | 安徽安力肽生物科技有限公司 | Pueraria flavone tablet and preparation method thereof |
| CN113398084A (en) * | 2021-07-02 | 2021-09-17 | 安徽省先锋制药有限公司 | Levetiracetam sustained release tablet and preparation method thereof |
| CN216488192U (en) * | 2021-12-13 | 2022-05-10 | 山东中信迪生电源有限公司 | Tabletting device for battery pressure surface gasket |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8980307B2 (en) | Compositions and methods for the sustained release of beta-alanine | |
| US11013251B2 (en) | Embedded liquid lubricants for tableting | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| CN102048884B (en) | Weight-losing composition containing guarana extract | |
| CN106722444A (en) | A kind of preparation method of sea-buckthorn chewing tablet | |
| CN115554388A (en) | Nutrition balance formula for improving female polycystic ovarian hormone level and production process | |
| CN107302960A (en) | A kind of vegetable protein solid beverage taken during body-building | |
| JP2022173374A (en) | oral composition | |
| JP6167357B1 (en) | Diabetes mellitus improvement preventive | |
| CN116712892A (en) | Nutrient balance liquid production equipment for improving female polycystic ovary hormone and formula thereof | |
| KR20000018977A (en) | Production process and food composition for adjusting weight and blood sugar prepared by using wax gourd and residual thereof | |
| JP7108992B1 (en) | Composition containing ingredient derived from pericarp of sea buckthorn | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| JP6095251B1 (en) | Diabetes mellitus improvement preventive | |
| CN117694480A (en) | Formula and preparation process of compound multidimensional solid beverage suitable for dietary nutrition supplement of people with high blood sugar | |
| CN1253734A (en) | Bittersquash extraxt sugar-reducing milk powder and its preparation process | |
| CN109315573A (en) | The manufacture craft and formula of a kind of pre- anti-aging health food or food | |
| US20050031686A1 (en) | Gastroresistant tablets for alimentary, dietetic and therapeutic use | |
| CN103229997A (en) | Calcium-zinc multivitamin tablets and preparation method thereof | |
| CN102578585A (en) | Soy protein sausage with health care role and processing and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |